Key points are not available for this paper at this time.
Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa (ClinicalTrials.gov numbers, NCT00098657 and NCT00083889 ClinicalTrials.gov).
Motzer et al. (2007) studied this question.